Background: Animal models suggest that red blood cell (RBC) damage incurred during storage can increase immunogenicity to some RBC antigens. We hypothesized that RBC irradiation, a source of oxidative damage, may result in higher RBC alloimmunization rates among transfusion recipients.
The irradiation of cellular blood components is effective in preventing transfusion-associated graft versus host disease (TA-GVHD). 1 Despite the clinical importance of this type of product modification, gamma irradiation is associated with negative adverse effects, such as damage to stored red blood cells (RBCs) . Although it is known that gamma irradiation leads to potassium and lactate dehydrogenase leakage from RBCs, 2, 3 several investigators [4] [5] [6] have demonstrated other forms of RBC injury after irradiation. For example, Anand and colleagues reported that gamma-irradiated RBC products (exposed to cesium 137)
were associated with lipid peroxidation and hemoglobin oxidation in RBCs: both processes reflect the development of reactive oxygen species and could lead to damage of the RBC membrane. 4 The results of another study 5 subsequently confirmed that irradiation did, in fact, perturb the RBC membrane, leading to increased osmotic fragility in vitro. Also, work by Antosik et al 6 showed that stored, irradiated RBCs (exposed to cobalt 60) had increased phosphatidylserine externalization. Thus, gamma irradiation can cause substantial injury to RBCs during their storage. Moreover, the results of 2 studies 8, 9 have shown that gamma-irradiated units also are
cleared more rapidly and demonstrate poorer recovery compared with nonirradiated units.
In addition to blunting the therapeutic benefit of RBC transfusion, increased clearance may have other hypothetical and unanticipated ramifications. For instance, a study by Hendrickson and study results showed that this clearance resulted in increased immunogenicity of the hen egg lysozyme, ovalbumin, and human Duffy b (HOD) antigen. 7 As such, and based in part on these animal-model data, we investigated the effect that gamma irradiation might have on the development of blood group alloantibodies in humans who had undergone transfusion. We hypothesized that the increased clearance associated with irradiated RBCs would lead to a higher alloimmunization rate for gamma-irradiated RBCs units, compared with historical control units from our facility. We speculated that the irradiation-associated RBC damage may serve as a type of danger signal to the immune systems of transfusion recipients, possibly causing these RBCs to be associated with a stronger immune response than nonirradiated units. To date, few large-scale studies of alloimmunization have examined the effect of such product modifications on blood-group antibody development. 10, 11 Also, to our knowledge, no studies have performed an extensive investigation of this type in a general, hospitalbased patient population.
Materials and Methods

Subjects, Inclusion Criteria, and Data Collection
In all the records that we reviewed, 154 patients met inclusion criteria for the experimental arm of the study. As detailed in Table 1 , this cohort was overwhelmingly male, which is consistent with the cohorts in previous studies at our facility. 12 This information also indicates that most blood group alloantibodies detected should have resulted from transfusion rather than pregnancy. As noted in Table 1 and Figures 1A and 1B Our study subjects were patients receiving care at the VA Connecticut Healthcare System (West Haven Campus), which is an approximately 360-bed, clinical-referral level I facility. Study information was extracted from a database described previously. 12 Data on subjects were retrospectively extracted from a paper-record database that included information regarding product modifications (including the irradiation status of each RBC unit) at our facility. Once we had identified the subjects, further inclusion in this study required that the patient had received at least 1 gamma-irradiated RBC unit and had undergone follow-up antibody screening 14 days or longer after receipt of the first irradiated RBC unit. 11 For any patient meeting the aforementioned inclusion criteria, we collected the following information from the electronic medical record (EMR): sex, primary diagnosis at time of RBC transfusion (or the indication for RBC transfusion), the total irradiated RBC units received, the number/specificity of pre-existing alloantibodies (ie, antibodies detected before receipt of an irradiated unit), the number/specificity of alloantibodies detected after receipt of the first irradiated RBC unit, and the total type and screens performed after receipt of the first irradiated unit. The alloimmunization rate associated with irradiated units was calculated as follows: To avoid inclusion of patients in both arms of the study, we checked the records for evidence of the patient having received any irradiated RBC units and crossreferenced data from the control and experimental arms, to avoid inclusion of the same subject in both databases. These study procedures were approved by the institutional review board at the study site.
Gamma Irradiation of RBC Units
During the time frame of the study, all irradiation was performed on site using a cesium 137 radiation source (Gammacell 3000 Elan, TeamBest) that had been installed at the facility in 2005. The irradiation source has undergone annual maintenance since its installation, including dose mapping, to ensure that appropriate exposure times and irradiation doses are delivered. An irradiation indicator label is also affixed to each irradiated unit to ensure adequate dosing on a case-by-case basis. Radiation doses at our facility during the study period ranged from 19 Gy to 33 Gy, with an average dose of 25 Gy delivered to the center of the RBC unit. Our facility maintains a guideline for irradiation based on the clinical history and/or medication regimens of the patient; the document we use in this process reflects the recommendations of published national and international experts. 13, 14 Requests for irradiation must be approved by a laboratory-medicine physician. We have a relatively small RBC inventory at our facility (90-100 total RBC units with 
7%]). Diseases categorized as Other included squamous-cell cancer of the head and neck (n
, and astrocytoma (n ¼ 1). Postop indicates postoperative; GI, gastrointestinal; MDS, myelodysplastic syndrome; NSCLC, non-small cell lung cancer.
units). As a result, it is our practice to provide irradiated units to the general patient population once it is clear that the primary intended recipient (who did require irradiation) no longer will be transfused with that unit. As such, it is common for general patients to receive irradiated RBC units.
RBC Products and Serologic Testing
All RBCs infused for the experimental and control arms of the study were stored in additive solution and were filtered/ leukoreduced at a donor center before storage. During the study, antibody screening at our facility involved a 3-cell screen with low-ionic strength solution (LISS) via the tube method (estimated at approximately two-thirds to threefourths of total types and screens) or a 3-cell screen via the gel method (ProVue, Ortho Clinical Diagnostics). We performed all antibody identification panels using the tube method during the study period.
Statistical Analysis
Descriptive statistics were performed using spreadsheet software (Excel, version 2010; Microsoft Corporation), and comparative statistics were performed using the Fisher exact test and the Mann-Whitney U test. A P value of less than .05 was deemed significant.
Results
Among the nonimmunosuppressed group, the most common diagnosis or indication for RBC transfusion was postoperative bleeding (36/83 [43.4%]), followed by general, non-malignant-neoplasm-associated anemia (23/83 [27.7%]). When comparing the nonimmunosuppressed group with the immunosuppressed group, we noted no significant differences in age at the time of receipt of the first irradiated unit or in the number of total follow-up antibody screens. The immunosuppressed group, however, received a significantly higher number of irradiated RBC units.
Among the 154 patients who received at least 1 irradiated unit, we noted that 3 patients developed new alloantibodies associated with these infusions, yielding an alloimmunization rate of 1.9%. As noted in Figure 2 , there was no significant difference between the study group alloimmunization rate of 1.9% and the control alloimmunization rate at our facility 
Discussion
Gamma irradiation of RBC units is an essential modification to prevent TA-GVHD in select patient populations. However, irradiation can also damage RBC units, resulting in leakage of RBC contents, membrane instability, and a higher postinfusion clearance rate. 19 We kept this damage in mind and took into consideration reports from animal models showing that injured
Figure 2
Comparison of alloimmunization rates between the experimental and control groups. We found no significant difference in the alloimmunization rate of our experimental group (of patients receiving RBCs that express the model HOD antigen clear rapidly and possess enhanced immunogenicity. 7 As a result, we hypothesized that irradiated RBCs may be associated with a higher alloimmunization rate compared with historical controls at our facility. However, our data showed that gamma irradiation was not associated with a significantly higher RBC alloimmunization rate in our patient population, which included a large percentage of individuals with immunocompetence.
During the design phase of our study, one of the major obstacles we anticipated was that most of the subjects who received irradiated blood products were likely to have immunosuppression; this fact could have negatively biased the alloimmunization rates that we observed. However, nonimmunosuppressed patients ended up constituting most of the subjects in our study; none of them had detectable RBC alloantibodies after receiving irradiated RBCs, despite numerous follow-up typing and screening tests. Given the modest size of the blood-bank inventory at the studied hospital, units that are irradiated for one patient but are not used are frequently transfused to other patients, particularly patients with urgent needs because of postoperative or gastrointestinal bleeding. It is unlikely that the lack of alloantibody detection in such patients with immunocompetence is due to our patient population being made up entirely of nonresponders (the pre-existing alloantibody rate in this group was 8%). Based on these factors, we believe that we avoided an underestimation of alloimmunization due to baseline immunosuppression in the study subjects.
Also, the only patients that we observed to develop new alloantibodies after receiving irradiated RBC units in our study were those with MDS, a group of patients classically thought to have immunosuppression because of their disease and/or the medical regimens used to treat MDS. However, the findings reported in relatively recent literature [15] [16] [17] suggest that MDS can be associated with high alloantibody-development rates. In fact, studies [15] [16] [17] have shown alloimmunization rates of 15% to 37% for patients with MDS or MDS-related disorders. Although beyond the scope of this investigation, future studies are warranted to explore the factor(s) that may predispose subsets of patients with MDS to develop blood group alloantibodies despite the apparent immunosuppressive nature of their underlying disorders.
Our study has certain limitations. First, ours was a singlesite, retrospective investigation involving a limited number of patients. Moreover, the average age of the immunosuppressed and nonimmunosuppressed patients was older than 69 years. It is possible that prospective studies in larger patient populations with a younger mean age might yield different results. Further, information regarding the timing between RBC-unit irradiation and subsequent infusion was not readily available for analysis. Several studies [4] [5] [6] have shown that gamma irradiation followed by prolonged RBC storage is associated with more substantial oxidative damage. We believe that it will be important to expand on the findings in this study with additional studies that specifically examine the immune response to freshly irradiated RBCs, as well as RBCs transfused after prolonged storage following irradiation.
Also, our study sample was small, involving approximately 150 patients in the experimental arm. This size was due partly to the stringent inclusion criteria regarding the need for follow-up screening tests. Larger studies may be beneficial to confirm our findings, particularly from institutions that routinely irradiate most or all RBC units in their inventories. Nevertheless, given the degree of follow-up observed and Indicates the total number of irradiated RBC units received by patients in the experimental arm and the total number of nonirradiated RBC units received by patients in the control arm.
the large, nonimmunosuppressed nature of the study population, we have substantial confidence in our results. Last, it must be considered that irradiation or other forms of RBC damage may alter the immunogenicity of some blood group antigens but not others.
In summary, our retrospective study could find no evidence supporting the hypothesis that irradiation-induced RBC damage is associated with higher rates of blood group antibody development. If necessary, irradiated RBC units likely can be provided to individuals who would not otherwise require such modification, without significant concerns for increased alloimmunization risk. Studies investigating RBC alloimmunization risk compared with storage duration after irradiation also may be informative. LM
